-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the news on September 3, Chia Tai Tianqing Pharmaceutical Co.
, Ltd.
has entered the administrative examination and approval stage with generic 4 types of everolimus tablets.
This product has not yet been approved for generic drugs in China.
In 2020, it will be approved by public medical institutions and The total sales scale of physical pharmacies in cities in China exceeds 100 million yuan
.
According to data from Meinenet, since 2018, Chia Tai Tianqing Pharmaceuticals has approved 9 new classified anti-tumor and immunomodulators for production, and 5 of them are the first imitations
.
, Ltd.
has entered the administrative examination and approval stage with generic 4 types of everolimus tablets.
This product has not yet been approved for generic drugs in China.
In 2020, it will be approved by public medical institutions and The total sales scale of physical pharmacies in cities in China exceeds 100 million yuan
.
According to data from Meinenet, since 2018, Chia Tai Tianqing Pharmaceuticals has approved 9 new classified anti-tumor and immunomodulators for production, and 5 of them are the first imitations
.
Source: official website of the State Drug Administration
Everolimus is an mTOR inhibitor developed by Novartis.
It is a derivative of mammalian rapamycin.
It forms a complex with immune binding proteins and interferes with the formation of regulatory proteins that control cell metabolism and proliferation.
It can inhibit tumors.
Triple anti-tumor effects of cell growth and proliferation, inhibition of tumor nutrition metabolism and anti-angiogenesis
.
It is a derivative of mammalian rapamycin.
It forms a complex with immune binding proteins and interferes with the formation of regulatory proteins that control cell metabolism and proliferation.
It can inhibit tumors.
Triple anti-tumor effects of cell growth and proliferation, inhibition of tumor nutrition metabolism and anti-angiogenesis
.
Global sales of everolimus
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
Everolimus was approved for the first time in Sweden in 2003, and then spread in Europe, the United States, Japan, etc.
, and won multiple indications.
In 2020, global sales reached 1.
535 billion U.
S.
dollars
.
, and won multiple indications.
In 2020, global sales reached 1.
535 billion U.
S.
dollars
.
Innovator product approved in January 2013 to enter the domestic market in 2017 into the national health insurance through negotiations, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) and China The total sales scale of urban physical pharmacies exceeds 100 million yuan
.
.
Sales of everolimus tablets in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
The terminal of Chinese public medical institutions is the "main battlefield" of everolimus, but the physical pharmacy terminal also maintains a good expansion trend, with a growth rate of 20.
13% in 2020, exceeding the 9.
68% growth rate of the terminal of Chinese public medical institutions
.
13% in 2020, exceeding the 9.
68% growth rate of the terminal of Chinese public medical institutions
.
Anti- tumor and immunomodulators approved by Chia Tai Tianqing Pharmaceutical Co.
, Ltd.
(new classification for production) since 2018
, Ltd.
(new classification for production) since 2018
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Meinenet, from 2018 to the present (calculated based on the start date of the state), 9 anti-tumor and immunomodulators under the new classification of CP Tianqing Pharmaceutical have been approved for marketing and deemed to have been reviewed.
Among them, mesylate Vatinib capsules (tied), fulvestrant injection, pomalidomide capsules, bendamustine hydrochloride for injection, azacitidine for injection (tied) were the first imitations
.
Among them, mesylate Vatinib capsules (tied), fulvestrant injection, pomalidomide capsules, bendamustine hydrochloride for injection, azacitidine for injection (tied) were the first imitations
.
Source: Mynet database, official website of the State Drug Administration
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of September 2nd, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of September 2nd, if there are any omissions, please correct me!
According to the news on September 3, Chia Tai Tianqing Pharmaceutical Co.
, Ltd.
has entered the administrative examination and approval stage with generic 4 types of everolimus tablets.
This product has not yet been approved for generic drugs in China.
In 2020, it will be approved by public medical institutions and The total sales scale of physical pharmacies in cities in China exceeds 100 million yuan
.
According to data from Meinenet, since 2018, Chia Tai Tianqing Pharmaceuticals has approved 9 new classified anti-tumor and immunomodulators for production, and 5 of them are the first imitations
.
, Ltd.
has entered the administrative examination and approval stage with generic 4 types of everolimus tablets.
This product has not yet been approved for generic drugs in China.
In 2020, it will be approved by public medical institutions and The total sales scale of physical pharmacies in cities in China exceeds 100 million yuan
.
According to data from Meinenet, since 2018, Chia Tai Tianqing Pharmaceuticals has approved 9 new classified anti-tumor and immunomodulators for production, and 5 of them are the first imitations
.
Source: official website of the State Drug Administration
Everolimus is an mTOR inhibitor developed by Novartis.
It is a derivative of mammalian rapamycin.
It forms a complex with immune binding proteins and interferes with the formation of regulatory proteins that control cell metabolism and proliferation.
It can inhibit tumors.
Triple anti-tumor effects of cell growth and proliferation, inhibition of tumor nutrition metabolism and anti-angiogenesis
.
It is a derivative of mammalian rapamycin.
It forms a complex with immune binding proteins and interferes with the formation of regulatory proteins that control cell metabolism and proliferation.
It can inhibit tumors.
Triple anti-tumor effects of cell growth and proliferation, inhibition of tumor nutrition metabolism and anti-angiogenesis
.
Global sales of everolimus
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
Everolimus was approved for the first time in Sweden in 2003, and then spread in Europe, the United States, Japan, etc.
, and won multiple indications.
In 2020, global sales reached 1.
535 billion U.
S.
dollars
.
, and won multiple indications.
In 2020, global sales reached 1.
535 billion U.
S.
dollars
.
Innovator product approved in January 2013 to enter the domestic market in 2017 into the national health insurance through negotiations, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) and China The total sales scale of urban physical pharmacies exceeds 100 million yuan
.
.
Sales of everolimus tablets in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
The terminal of Chinese public medical institutions is the "main battlefield" of everolimus, but the physical pharmacy terminal also maintains a good expansion trend, with a growth rate of 20.
13% in 2020, exceeding the 9.
68% growth rate of the terminal of Chinese public medical institutions
.
13% in 2020, exceeding the 9.
68% growth rate of the terminal of Chinese public medical institutions
.
Anti- tumor and immunomodulators approved by Chia Tai Tianqing Pharmaceutical Co.
, Ltd.
(new classification for production) since 2018
, Ltd.
(new classification for production) since 2018
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Meinenet, from 2018 to the present (calculated based on the start date of the state), 9 anti-tumor and immunomodulators under the new classification of CP Tianqing Pharmaceutical have been approved for marketing and deemed to have been reviewed.
Among them, mesylate Vatinib capsules (tied), fulvestrant injection, pomalidomide capsules, bendamustine hydrochloride for injection, azacitidine for injection (tied) were the first imitations
.
Among them, mesylate Vatinib capsules (tied), fulvestrant injection, pomalidomide capsules, bendamustine hydrochloride for injection, azacitidine for injection (tied) were the first imitations
.
Source: Mynet database, official website of the State Drug Administration
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of September 2nd, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of September 2nd, if there are any omissions, please correct me!
According to the news on September 3, Chia Tai Tianqing Pharmaceutical Co.
, Ltd.
has entered the administrative examination and approval stage with generic 4 types of everolimus tablets.
This product has not yet been approved for generic drugs in China.
In 2020, it will be approved by public medical institutions and The total sales scale of physical pharmacies in cities in China exceeds 100 million yuan
.
According to data from Meinenet, since 2018, Chia Tai Tianqing Pharmaceuticals has approved 9 new classified anti-tumor and immunomodulators for production, and 5 of them are the first imitations
.
, Ltd.
has entered the administrative examination and approval stage with generic 4 types of everolimus tablets.
This product has not yet been approved for generic drugs in China.
In 2020, it will be approved by public medical institutions and The total sales scale of physical pharmacies in cities in China exceeds 100 million yuan
.
According to data from Meinenet, since 2018, Chia Tai Tianqing Pharmaceuticals has approved 9 new classified anti-tumor and immunomodulators for production, and 5 of them are the first imitations
.
Source: official website of the State Drug Administration
Everolimus is an mTOR inhibitor developed by Novartis.
It is a derivative of mammalian rapamycin.
It forms a complex with immune binding proteins and interferes with the formation of regulatory proteins that control cell metabolism and proliferation.
It can inhibit tumors.
Triple anti-tumor effects of cell growth and proliferation, inhibition of tumor nutrition metabolism and anti-angiogenesis
.
It is a derivative of mammalian rapamycin.
It forms a complex with immune binding proteins and interferes with the formation of regulatory proteins that control cell metabolism and proliferation.
It can inhibit tumors.
Triple anti-tumor effects of cell growth and proliferation, inhibition of tumor nutrition metabolism and anti-angiogenesis
.
Global sales of everolimus
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
Everolimus was approved for the first time in Sweden in 2003, and then spread in Europe, the United States, Japan, etc.
, and won multiple indications.
In 2020, global sales reached 1.
535 billion U.
S.
dollars
.
, and won multiple indications.
In 2020, global sales reached 1.
535 billion U.
S.
dollars
.
Innovator product approved in January 2013 to enter the domestic market in 2017 into the national health insurance through negotiations, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) and China The total sales scale of urban physical pharmacies exceeds 100 million yuan
.
Hospital hospital hospital pharmacy pharmacy pharmacy.
Sales of everolimus tablets in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
The terminal of Chinese public medical institutions is the "main battlefield" of everolimus, but the physical pharmacy terminal also maintains a good expansion trend, with a growth rate of 20.
13% in 2020, exceeding the 9.
68% growth rate of the terminal of Chinese public medical institutions
.
13% in 2020, exceeding the 9.
68% growth rate of the terminal of Chinese public medical institutions
.
Anti- tumor and immunomodulators approved by Chia Tai Tianqing Pharmaceutical Co.
, Ltd.
(new classification for production) since 2018
Tumor tumor tumor, Ltd.
(new classification for production) since 2018
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Meinenet, from 2018 to the present (calculated based on the start date of the state), 9 anti-tumor and immunomodulators under the new classification of CP Tianqing Pharmaceutical have been approved for marketing and deemed to have been reviewed.
Among them, mesylate Vatinib capsules (tied), fulvestrant injection, pomalidomide capsules, bendamustine hydrochloride for injection, azacitidine for injection (tied) were the first imitations
.
Among them, mesylate Vatinib capsules (tied), fulvestrant injection, pomalidomide capsules, bendamustine hydrochloride for injection, azacitidine for injection (tied) were the first imitations
.
Source: Mynet database, official website of the State Drug Administration
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of September 2nd, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of September 2nd, if there are any omissions, please correct me!
